Aurora Medical Center of Washington County, INC.
Aurora Medical Center of Washington County, INC. was paid $3.25M by Medicaid between Jan 2018 and Dec 2024, across 88 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 22% of everything it billed.
33Billing provider infoAURORA MEDICAL CENTER OF WASHINGTON COUNTY, INC.
HARTFORD, WI 53027
HARTFORD, WI 53027
33aNPI1760420103assigned 06/04/2006
33bProvider typeOccupational Therapist
28Total paid$3.25M
24GClaims132,918
24DCodes billed88
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Occupational Therapist providers in Wisconsin
Rank by total paid#5 of 43
Median peer was paid$26K
This provider vs. median125×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,431 | $424K | |
| 2019 | 16,232 | $407K | |
| 2020 | 16,114 | $420K | |
| 2021 | 21,477 | $497K | |
| 2022 | 21,953 | $543K | |
| 2023 | 21,504 | $489K | |
| 2024incomplete | 18,207 | $473K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 22% | 22,000 | 7,691 | $723K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 6,479 | 5,795 | $415K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 8.9% | 13,066 | 4,721 | $290K |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.9% | 2,160 | 1,891 | $288K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.4% | 4,629 | 4,151 | $272K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.4% | 2,908 | 2,604 | $174K |
| 80053 | Comprehensive metabolic panel | 3.6% | 5,910 | 4,955 | $117K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.2% | 4,110 | 2,641 | $103K |
| 97161 | 2.9% | 2,177 | 2,015 | $94K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 1,129 | 1,043 | $93K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 2.6% | 3,483 | 1,545 | $85K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.4% | 1,150 | 1,055 | $78K |
76 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 925 | $70K |
| 97162 | 1.6% | 1,432 | $53K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 6,739 | $44K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.2% | 960 | $39K |
| 97035 | 1.0% | 2,977 | $34K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 644 | $29K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 363 | $27K |
| 81025 | <1% | 1,880 | $21K | |
| 84484 | <1% | 2,087 | $20K | |
| 97116 | <1% | 1,333 | $20K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 308 | $17K |
| 82962 | <1% | 990 | $13K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 564 | $12K |
| 83690 | <1% | 1,820 | $12K | |
| 82077 | <1% | 477 | $12K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 84 | $10K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 123 | $9K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 448 | $7K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 172 | $7K |
| 81001 | <1% | 1,715 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 109 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 27 | $5K |
| 83735 | <1% | 935 | $5K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 51 | $4K |
| 81003 | <1% | 603 | $4K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 63 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 74 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,238 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 58 | $2K |
| 97165 | <1% | 58 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 60 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,810 | $2K |
| 85610 | <1% | 329 | $2K | |
| 85379 | <1% | 183 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,603 | $1K |
| 83605 | <1% | 175 | $1K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,530 | $1K |
| 80143 | <1% | 87 | $1K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,766 | $1K |
| 80179 | <1% | 74 | $1K | |
| 97597 | <1% | 17 | $984.21 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 30 | $847.78 |
| 83880 | <1% | 27 | $819.52 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $583.55 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,085 | $551.69 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 30 | $519.92 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15 | $478.06 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 30 | $348.91 |
| 77002 | <1% | 16 | $325.44 | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $321.31 |
| 82565 | <1% | 14 | $290.45 | |
| 93971 | <1% | 14 | $287.89 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,198 | $275.21 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,207 | $206.64 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13 | $179.25 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 572 | $29.85 |
| 36415 | Collection of venous blood by venipuncture | <1% | 607 | $5.80 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 498 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 1,643 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 889 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,680 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 1,061 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 269 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 2,856 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 68 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 533 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 18 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 2,484 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 523 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 73 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 50 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 82 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 58 | $0.00 |
| 71046 | Radiologic examination, chest; 2 views | 0% | 39 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 29 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 89 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (VP MANAGED HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.